Consider STIVARGA® (regorafenib) in 3rd line after 2 or more standard chemotherapy-containing regimens

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) list regorafenib (STIVARGA) as a potential treatment option for patients who have been previously treated with at least 2 chemo-based therapies (Category 2A)1,2*

Potential treatment algorithms1,2†

Potential treatment algorithms. Visit hcp.stivarga-us.com to see full safety and Prescribing Information, including Boxed Warning.

Designated Category 2A by the National Comprehensive Cancer Network® (NCCN®).1,2*

Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.2.2021 and for Rectal Cancer V.1.2021. © 2021 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data become available.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

In the CORRECT trial, 27% and 25% of patients received 1 or 2 prior lines of therapy in the STIVARGA and placebo arms, respectively3

  • Historical KRAS status was assessed (59% mutant-type, 41% KRAS wild-type)4
  • All patients enrolled in the CORRECT trial had an Eastern Cooperative Oncology Group performance status of 0 or 14

CORRECT (COloRectal cancer treated with REgorafenib or plaCebo after failure of standard Therapy) was a large, international, placebo-controlled, double-blind, randomized trial.4